Tom Norton

Could the new Vermont Drug Transparency law “lead the US Pharmaceutical industry to an awful end”? Tom Norton reports.

California is in the process of potentially establishing a new, disruptive healthcare policy that is proving to be very concerning to the American Rx industry, writes Tom Norton.

Even though pharma's “dark days” are fading away, the chill of the last few months will not soon be forgotten, writes Tom Norton.

As US pharma continues to ponder its “winter of discontent”, the question that leaders of industry have to be asking themselves is, “How did things get this bad?” Tom Norton reports.

As that nation heads towards its first presidential primaries of the 2016 election, pharmaceutical executives should take a few minutes to consider where the leading candidates stand on U.S. Rx policy. Tom Norton takes a look.

What are the chances that Rx price controls will actually take hold in the U.S. in the near future? Tom Norton believes the answer to that question can summed up in one word: California.